Inflammatory Bowel Diseases Clinical Trial
Official title:
Feasibility of a Care Team-Focused Action Plan to Improve Quality of Care for Children and Adolescents With Inflammatory Bowel Disease
The goal of this interventional study is to test the feasibility of a new communication tool, call MyIBD, in youth ages 13 to 19 years with inflammatory bowel disease. The main question[s] it aims to answer are: - Is the MyIBD communication tool feasible to use in everyday clinical practice? - Does the MyIBD tool have potential to improve patients' self-management skills and the quality of care they receive? Participants who receive the MyIBD intervention will complete surveys about their care at three times points - at study enrollment, at 6 months, and at 12 months. The surveys will help the research team learn about the feasibility of using MyIBD in practice and about any effects on patients' self-management skills and quality of care. Researchers will compare those receiving a MyIBD document to a randomly selected control group (patients receiving usual care for pediatric inflammatory bowel disease) to see if self-management skills and quality of care differ between the groups.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | September 2025 |
Est. primary completion date | September 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 13 Years to 19 Years |
Eligibility | Inclusion Criteria: - age 13-19 years old at time of recruitment; AND - diagnosis at least 3 months earlier of Crohn's disease, ulcerative colitis, or indeterminate colitis (to exclude families who have not had sufficient time to become familiar with condition and/or clinic personnel); AND - receiving ongoing care at UNC (at least one visit in the past year) Exclusion Criteria: - speaker of a language other than English or Spanish |
Country | Name | City | State |
---|---|---|---|
United States | University of North Carolina-Chapel Hill School of Medicine | Chapel Hill | North Carolina |
Lead Sponsor | Collaborator |
---|---|
University of North Carolina, Chapel Hill | National Center for Advancing Translational Sciences (NCATS) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Number of overall participants who completed a primary care health supervision visit in the past year, baseline | Number (0-60) of participants who report having a primary care health supervision visit with a primary care provider in the past year | Measured by self-report in baseline survey; reported at end of study year 1 | |
Other | Number of overall participants who completed a primary care health supervision visit in the past year, 12 months | Number (0-60) of participants who report having a primary care health supervision visit with a primary care provider in the past year | Measured by self-report in 12-month survey; reported at end of study year 2 | |
Other | Number of overall participants who completed special vaccine recommendations, baseline | Number (0-unknown) of participants who report having completed all special vaccines recommended by IBD clinician (such as Hepatitis B booster dose, pneumococcal polysaccharide vaccine) | Measured by self-report in baseline survey; reported at end of study year 1 | |
Other | Number of overall participants who completed special vaccine recommendations, 12 months | Number (0-unknown) of participants who report having completed all special vaccines recommended by IBD clinician (such as Hepatitis B booster dose, pneumococcal polysaccharide vaccine) | Measured by self-report in 12-month survey; reported at end of study year 2 | |
Other | Number of overall participants who participated in mood disorder screening in the past year, baseline | Number (0-60) of participants who report participating in any mood disorder screening in the past year | Measured by self-report in baseline survey; reported at end of study year 1 | |
Other | Number of overall participants who participated in mood disorder screening in the past year, 12 months | Number (0-60) of participants who report participating in any mood disorder screening in the past year | Measured by self-report in 12-month survey; reported at end of study year 2 | |
Other | Average number of non-injury-related visits to an emergency department (ED) in the past year, baseline | Total count of non-injury-related ED visits by participants in the past year divided by the total number of participants | Measured by self-report in baseline survey; reported at end of study year 1 | |
Other | Average number of non-injury-related visits to an emergency department (ED) in the past year, 12 months | Total count of non-injury-related ED visits by participants in the past year divided by the total number of participants | Measured by self-report in 12-month survey; reported at end of study year 2 | |
Primary | Number of overall participants recruited and randomized | Number (0-60) will be an indicator of feasibility of implementing MyIBD in practice. | Measured and reported at the end of study year 1 | |
Primary | Number of intervention group participants who receive a MyIBD document | Number (0-30) of intervention-group participants who receive a MyIBD document will estimate the degree of completion of the intervention in practice. | Measured and reported at the end of study year 1 | |
Primary | Number of overall participants retained through baseline survey | Number (0-60) of participants who complete the baseline survey | Measured and reported at the end of study year 1 | |
Primary | Number of overall participants retained through 6-month survey | Number (0-60) of participants who complete the 6-month survey | Measured and reported at the mid-point of study year 2 | |
Primary | Number of overall participants retained through 12-month survey | Number (0-60) of participants who complete the 12-month survey | Measured and reported at end of study year 2 | |
Primary | Number of control group participants who receive a MyIBD document | Number (0-30) of control-group participants who (inappropriately) receive a MyIBD document is an indicator of contamination, or spreading the intervention in practice to the control group. | Measured and reported at the end of study year 1 | |
Primary | Number of intervention group participants who agree or completely agree that MyIBD is an acceptable intervention using the Acceptability of Intervention Measure | Measured in the 12-month participant survey using the Acceptability of Intervention Measure (AIM), a four-item scale with five Likert-type response options from 1=Completely disagree to 5=Completely agree. Item scores are averaged to yield a scale score, with 1 indicating the lowest level of acceptability and 5 indicating the highest level. | Reported at the end of study year 2 | |
Primary | Number of intervention group participants who agree or completely agree that MyIBD is an appropriate intervention using the Intervention Appropriateness Measure | Measured in the 12-month participant survey using the Intervention Appropriateness Measure (IAM), a four-item scale with five Likert-type response options from 1=Completely disagree to 5=Completely agree. Item scores are averaged to yield a scale score, with 1 indicating the lowest level of appropriateness and 5 indicating the highest level. | Reported at the end of study year 2 | |
Secondary | Mean self-management score on the Partners in Health scale at baseline | Measured in the baseline participant survey using the Partners in Health Scale, a 12-item survey with 9 Likert-type response options from 0=Very Little/Never to 8=A Lot/Always. Item scores are summed to yield a total scale score from 0, indicating the lowest level of self-management skill, to 96, indicating the highest level of self-management skill. | Measured in each participant's baseline survey; reported at end of study year 1 | |
Secondary | Mean self-management score on the Partners in Health scale at 6 months | Measured in the 6-month participant survey using the Partners in Health Scale, a 12-item survey with 9 Likert-type response options from 0=Very Little/Never to 8=A Lot/Always. Item scores are summed to yield a total scale score from 0, indicating the lowest level of self-management skill, to 96, indicating the highest level of self-management skill. | Measured in each participant's 6-month survey; reported at end of study year 2 | |
Secondary | Mean self-management score on the Partners in Health scale at 12 months | Measured in the 12-month participant survey using the Partners in Health Scale, a 12-item survey with 9 Likert-type response options from 0=Very Little/Never to 8=A Lot/Always. Item scores are summed to yield a total scale score from 0, indicating the lowest level of self-management skill, to 96, indicating the highest level of self-management skill. | Measured in each participant's 12-month survey; reported at end of study year 2 | |
Secondary | Mean perceived Quality of Care score at baseline using the Patient Assessment of Chronic Illness Care survey | Measured in the baseline participant survey using the Patient Assessment of Chronic Illness Care scale, a 20-item survey with 5 Likert-type responses from 1=None of the time to 5=Always. Item scores are averaged to yield an overall scale score between 1 and 5, with 1 indicating the lowest perceived care quality and 5 indicating the highest. | Measured in each participant's baseline survey; reported at end of study year 1 | |
Secondary | Mean perceived Quality of Care score at 12 months using the Patient Assessment of Chronic Illness Care survey | Measured in the 12-month participant survey using the Patient Assessment of Chronic Illness Care scale, a 20-item survey with 5 Likert-type responses from 1=None of the time to 5=Always. Item scores are averaged to yield an overall scale score between 1 and 5, with 1 indicating the lowest perceived care quality and 5 indicating the highest. | Measured in each participant's 12-month survey; reported at end of study year 2 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04046913 -
The ADDapt Diet in Reducing Crohn's Disease Inflammation
|
N/A | |
Active, not recruiting |
NCT04989907 -
A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Switzerland
|
||
Recruiting |
NCT05316584 -
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
|
N/A | |
Active, not recruiting |
NCT04990258 -
A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Infliximab to Subcutaneous Infliximab CT-P13 Remsima®SC
|
||
Completed |
NCT06216223 -
Laser Versus Surgery in Anal Diseases in Inflammatory Bowel Patients
|
N/A | |
Enrolling by invitation |
NCT06015789 -
Self-care in Patients Affected by Inflammatory Bowel Disease and Caregivers' Contribution to Self-care
|
||
Recruiting |
NCT06065995 -
StoMakker Mobile Application
|
N/A | |
Recruiting |
NCT03282786 -
Comparison of Carbon Dioxide (CO2) to Air Insufflation in Colonoscopy in Patients With Inflammatory Bowel Disease
|
N/A | |
Recruiting |
NCT06002074 -
SMART Program Impact on Quality of Life in Inflammatory Bowel Diseases
|
N/A | |
Recruiting |
NCT04960826 -
Study of an Environmental Risk Factor in Crohn's Disease
|
||
Recruiting |
NCT05413941 -
Internet-based Cognitive Behavioral Therapy in Inflammatory Bowel Disease
|
N/A | |
Completed |
NCT03668249 -
A Study to Characterize Multidimensional Model to Predict the Course of Crohn's Disease (CD)
|
||
Completed |
NCT00721812 -
A First Time In Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK1399686
|
Phase 1 | |
Recruiting |
NCT05809999 -
IBD Neoplasia Surveillance RCT
|
N/A | |
Recruiting |
NCT04138225 -
The Ecological Role of Yeasts in the Human Gut
|
||
Recruiting |
NCT04991324 -
Cholecalciferol Comedication in IBD - the 5C-study
|
Phase 3 | |
Completed |
NCT03173144 -
Chronic Inflammatory Disease, Lifestyle and Treatment Response
|
||
Not yet recruiting |
NCT05043818 -
A Clinical Study on the Screening of Intestinal Biomarkers in IBD Patients With Depression
|
||
Recruiting |
NCT03042091 -
Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery
|
Early Phase 1 | |
Not yet recruiting |
NCT02858557 -
The Effect of Diet on Microbial Profile and Disease Outcomes in Patients With Inflammatory Bowel Diseases
|
N/A |